Use of veno-venous extracorporeal life support in a patient with cytomegalovirus and Pneumocystis jiroveci related respiratory failure due to thymoma associated immunodeficiency: a case report

Although the use of extracorporeal life support (ECLS) treatment is increasing rapidly, its use in immunocompromised patients is still under debate as infections are a main predictor of poor outcome during ECLS therapy. Predicting the prognosis for a specific type of immunocompromised patient is challenging and is depending on the underlying disease and the amount of accumulated organ damage that has occurred.